Takeda signs US$600M AI drug discovery deal with Insilico

Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboratio

Related Stories

📰

Understanding Cache Misses: The Hidden Cost of AI Operations

📰

Embracing cloud upgrades: No need for blind faith

AI Giants Should Compensate for Content, Urges Australia's Shadow Arts Minister

📰

NVIDIA BioNeMo Lights the Path for Anthropic's Claude AI Breakthroughs